MAPT and Alzheimer disease: Notably, tau pathology emerges much closer to symptom onset than Aβ in AD [1, 2], as revealed by positron-emission-tomography (PET) [3, 4], biofluid biomarkers [5], and post-mortem examinations [6, 7].